Picard Announces Appointment of Two New Members to its Board of Directors
Picard Medical (NYSE American: PMI), parent company of SynCardia Systems LLC, has announced the appointment of two new members to its Board of Directors following its initial public offering. The company, known for developing the first U.S. and Canadian commercially-approved total artificial heart, has appointed Sam Van and George Ye to strengthen its board leadership.
Sam Van, founder and CEO of SRO Partners, brings extensive capital markets experience from roles at Freedom U.S. Markets, NYSE, and various board positions. George Ye contributes significant medical device industry expertise from leadership positions at Edwards Lifesciences, Abbott Laboratories, and Johnson & Johnson, particularly in global markets.
Picard Medical (NYSE American: PMI), società madre di SynCardia Systems LLC, ha annunciato la nomina di due nuovi membri nel suo Consiglio di Amministrazione a seguito della sua offerta pubblica iniziale. L'azienda, nota per aver sviluppato il primo cuore artificiale totalmente approvato commercialmente negli Stati Uniti e in Canada, ha inserito in consiglio Sam Van e George Ye per rafforzare la leadership del board.
Sam Van, fondatore e CEO di SRO Partners, apporta una vasta esperienza nei mercati dei capitali maturata in ruoli presso Freedom U.S. Markets, il NYSE e varie posizioni in consigli di amministrazione. George Ye offre una profonda competenza nel settore dei dispositivi medici, acquisita in ruoli di leadership presso Edwards Lifesciences, Abbott Laboratories e Johnson & Johnson, con particolare attenzione ai mercati globali.
Picard Medical (NYSE American: PMI), empresa matriz de SynCardia Systems LLC, ha anunciado el nombramiento de dos nuevos miembros en su Junta Directiva tras su oferta pública inicial. La compañía, conocida por desarrollar el primer corazón artificial totalmente aprobado comercialmente en EE. UU. y Canadá, ha incorporado a Sam Van y George Ye para reforzar el liderazgo del consejo.
Sam Van, fundador y CEO de SRO Partners, aporta amplia experiencia en los mercados de capitales por su trayectoria en Freedom U.S. Markets, la NYSE y varios cargos en juntas directivas. George Ye suma un sólido conocimiento de la industria de dispositivos médicos gracias a sus cargos de liderazgo en Edwards Lifesciences, Abbott Laboratories y Johnson & Johnson, especialmente en mercados globales.
Picard Medical (NYSE American: PMI), SynCardia Systems LLC의 모회사,는 기업공개(IPO) 이후 이사회에 두 명의 신임 이사를 선임했다고 발표했습니다. 미국과 캐나다에서 상업적으로 승인된 최초의 전 인공심장을 개발한 회사로 알려진 Picard Medical은 이사회 리더십 강화를 위해 Sam Van과 George Ye를 임명했습니다.
SRO Partners의 창립자 겸 CEO인 Sam Van은 Freedom U.S. Markets, NYSE 및 여러 이사회 경력을 통해 자본시장 분야의 폭넓은 경험을 제공합니다. George Ye는 Edwards Lifesciences, Abbott Laboratories, Johnson & Johnson에서의 리더십 경험을 바탕으로 특히 글로벌 시장에서 의료기기 산업에 대한 깊은 전문성을 가져옵니다.
Picard Medical (NYSE American: PMI), société mère de SynCardia Systems LLC, a annoncé la nomination de deux nouveaux membres au sein de son conseil d'administration à la suite de son introduction en bourse. L'entreprise, reconnue pour avoir développé le premier cœur artificiel entièrement commercialisé approuvé aux États-Unis et au Canada, a nommé Sam Van et George Ye afin de renforcer la gouvernance du conseil.
Sam Van, fondateur et PDG de SRO Partners, apporte une vaste expérience des marchés de capitaux acquise chez Freedom U.S. Markets, la NYSE et au sein de plusieurs conseils d'administration. George Ye apporte une solide expertise dans le secteur des dispositifs médicaux, acquise dans des postes de direction chez Edwards Lifesciences, Abbott Laboratories et Johnson & Johnson, notamment sur les marchés mondiaux.
Picard Medical (NYSE American: PMI), Muttergesellschaft von SynCardia Systems LLC, hat nach seinem Börsengang zwei neue Mitglieder in den Verwaltungsrat berufen. Das Unternehmen, bekannt für die Entwicklung des ersten in den USA und Kanada kommerziell zugelassenen totalen Kunstherzens, berief Sam Van und George Ye, um die Führung des Vorstands zu stärken.
Sam Van, Gründer und CEO von SRO Partners, bringt umfassende Erfahrungen aus den Kapitalmärkten mit, unter anderem aus Positionen bei Freedom U.S. Markets, der NYSE und mehreren Aufsichtsräten. George Ye bringt bedeutende Expertise aus der Medizintechnikbranche mit, erworben in Führungspositionen bei Edwards Lifesciences, Abbott Laboratories und Johnson & Johnson, insbesondere im globalen Marktumfeld.
- Addition of experienced capital markets expert with IPO and public company expertise
- Strengthening of board with seasoned MedTech executive having global market experience
- Strategic timing of appointments following IPO to support public company transition
- None.
Appointments strengthen Picard’s Board with proven expertise in capital markets and global MedTech leadership
TUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the appointment of two new members that will serve on its Board of Directors, Sam Van and George Ye. Both were appointed following the closing of the initial public offering and have deep leadership experience in complementary areas to advise the company in its next stage as a public company.
“We are thrilled to welcome Sam and Geore to our Board,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc. “Sam brings deep expertise in financial and capital markets leadership across both public and private companies. George adds decades of experience in healthcare and medical technology, with a strong record in commercial execution and product strategy. Their combined perspectives will be invaluable as we advance our mission and grow as a public company.”
Mr. Van is the founder and Chief Executive Officer of SRO Partners. He previously served as Head of Advisory Services and Senior Vice President of Freedom U.S. Markets, a division of Freedom Holding Corp. (Nasdaq: FRHC), and as President and Director of Deltec Investment Adviser Limited. Earlier in his career, Mr. Van held senior leadership positions at the New York Stock Exchange, including Director of International Listings, where he originated more than 60 new listings, and Senior Examiner in NYSE Regulation. He has also served on the boards of Reed’s Inc., Relm Insurance Limited (Bermuda), and Phoenix Motor, Inc. Mr. Van began his career as an examiner with FINRA. He earned an MBA from Cornell University’s Johnson Graduate School of Management and a BS in Finance from St. John’s University.
Mr. Ye is a seasoned executive with extensive leadership experience in the medical device industry. He served in a variety of senior roles at Edwards Lifesciences (NYSE: EW), including Senior Vice President and General Manager for the Greater China Region, Vice President and General Manager for Japan Surgical, and Senior Director for Japan and Asia Pacific Strategy. Prior to Edwards, Mr. Ye held leadership positions at Abbott Laboratories and Johnson & Johnson, where he built a strong track record across global markets. He holds a Bachelor of Science in Chemical Engineering and an MBA, both from Northwestern University.
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
Picard Medical, Inc./SynCardia Systems, LLC
General/Media
Brittany Lanza
FAQ
Who are the new board members appointed to Picard Medical (PMI)?
What is Sam Van's background and experience before joining Picard Medical's board?
What experience does George Ye bring to Picard Medical's board?
Why did Picard Medical (PMI) appoint these new board members?
What is Picard Medical's (PMI) main product focus?
